Scholarlink

Background/Objectives <p>Chronic hemodialysis is a well-established supportive therapy for patients with end-stage kidney disease. However, this therapy is rarely implemented in low-income countries because of its high cost. We herein report a single-center experience in one of the poorest countries in the world, i.e., Niger, involving patients in whom hemodialysis was initiated.</p> Patients and methods <p>This cross-sectional study included all incident patients presenting with serum creatinine levels greater than 1000 µmol/L between January 2018 and December 2022. All patients agreed to undergo self-funded chronic hemodialysis. Survival was assessed as of December 2024. A total of 544 patients initiated hemodialysis therapy. Among them, 423 (77.8%) underwent hemodialysis for less than 3 months: 240 (57%) died, 57 (13.5%) recovered renal function, and the others were either lost to follow-up or decided to discontinue hemodialysis. Only 121 patients (22.2%) who had undergone hemodialysis for the first 3 months were able to embark on a chronic hemodialysis program; most were male (sex ratio, 2.7). Their mean age was 48 years. Most patients (62%) were from rural areas. Additionally, 66% had low income, and 52% lived very far from the dialysis facility. Vascular access was predominantly a central venous catheter (75%). Non-adherence to hemodialysis was observed in 76% of patients. Dropouts and loss to follow-up occurred in 15.7% and 29% of cases, respectively. At the end of follow-up, only 10 patients (8.3%) were still alive.</p> Conclusions <p>These findings call into question the utility of chronic hemodialysis in very low-income countries given its high cost and substantial mortality. When feasible, kidney transplantation abroad should be considered as supportive therapy as soon as the absence of renal recovery is established.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-center cross-sectional study of outcomes in hemodialysis patients in Niger: experience from the hemodialysis center at Zinder National Hospital

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月5日

查看全文
  • Hassane Moussa Diongolé,
  • Djibril Ahmed Alatinine,
  • Maman Bachir Goni dit Alassan,
  • Chaibou Laouali,
  • Djibrilla Bonkano,
  • Assoumane Zabeirou Hanahi,
  • Lionel Rostaing

摘要

Background/Objectives

Chronic hemodialysis is a well-established supportive therapy for patients with end-stage kidney disease. However, this therapy is rarely implemented in low-income countries because of its high cost. We herein report a single-center experience in one of the poorest countries in the world, i.e., Niger, involving patients in whom hemodialysis was initiated.

Patients and methods

This cross-sectional study included all incident patients presenting with serum creatinine levels greater than 1000 µmol/L between January 2018 and December 2022. All patients agreed to undergo self-funded chronic hemodialysis. Survival was assessed as of December 2024. A total of 544 patients initiated hemodialysis therapy. Among them, 423 (77.8%) underwent hemodialysis for less than 3 months: 240 (57%) died, 57 (13.5%) recovered renal function, and the others were either lost to follow-up or decided to discontinue hemodialysis. Only 121 patients (22.2%) who had undergone hemodialysis for the first 3 months were able to embark on a chronic hemodialysis program; most were male (sex ratio, 2.7). Their mean age was 48 years. Most patients (62%) were from rural areas. Additionally, 66% had low income, and 52% lived very far from the dialysis facility. Vascular access was predominantly a central venous catheter (75%). Non-adherence to hemodialysis was observed in 76% of patients. Dropouts and loss to follow-up occurred in 15.7% and 29% of cases, respectively. At the end of follow-up, only 10 patients (8.3%) were still alive.

Conclusions

These findings call into question the utility of chronic hemodialysis in very low-income countries given its high cost and substantial mortality. When feasible, kidney transplantation abroad should be considered as supportive therapy as soon as the absence of renal recovery is established.